<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258842</url>
  </required_header>
  <id_info>
    <org_study_id>10-SBUS-6-FON-02</org_study_id>
    <nct_id>NCT01258842</nct_id>
  </id_info>
  <brief_title>Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Trial of the Effects of Prophylactic Bifidobacterium Lactis HN019 Supplementation on the Incidence of Influenza Infection in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fonterra Research Centre</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fonterra Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of
      developing physician- and laboratory-confirmed influenza infection at any time during the
      12-week supplementation period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influenza infection</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom duration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of subjects that reports at least one adverse event (regardless of cause) during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">426</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>B. lactis HN019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium lactis HN019</intervention_name>
    <description>B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks</description>
    <arm_group_label>B. lactis HN019</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sachet, consumed once per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy free-living men and women aged 18 to 60 years

          -  Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and overweight)

          -  Subject owns a refrigerator and is willing to keep study product refrigerated at all
             times

          -  Ability of the participant (in the investigator's opinion) to comprehend the full
             nature and purpose of the study, including possible risks and side effects

          -  Consent to the study and willing to comply with study product and methods

        Exclusion Criteria:

          -  Influenza vaccination in last 6 months, or any other vaccination in previous 15 days

          -  Clinically significant underlying systemic illness that may preclude the subject's
             ability to complete the trial

          -  Chronic nasal, laryngeal, pleural, or respiratory condition that could mimic or
             obscure symptoms of influenza (e.g. chronic allergic rhinitis, asthma, COPD, as
             determined by medical history and baseline physical examination)

          -  Chronic use of medication(s) that could suppress or prevent flu-like symptoms (eg,
             antihistamines, cough medicines; echinacea, high-dose vitamin C)

          -  Use of medication(s) within the previous 3 months that affect immune response (eg,
             antibiotics)

          -  Contraindication to dairy products or any other substance in the study product (eg,
             lactose intolerance)

          -  History of alcohol, drug, or medication abuse

          -  Pregnant or lactating female, or pregnancy planned during study period

          -  Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 3
             months of screening

          -  Participation in another study with any investigational product within 3 months of
             screening

          -  Investigator believes that the participant may be uncooperative and/or noncompliant,
             and should therefore not participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Clerici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milano University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Clementi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tisha Golden</last_name>
    <email>tisha.golden@sprim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Rosen, MD</last_name>
      <phone>305-445-5637</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Remedica, LLC</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rica Stamatin, MD</last_name>
      <phone>248-650-7870</phone>
    </contact>
    <investigator>
      <last_name>Rica Stamatin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2010</study_first_posted>
  <last_update_submitted>December 10, 2010</last_update_submitted>
  <last_update_submitted_qc>December 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pramod Gopral, PhD</name_title>
    <organization>Fonterra Research Centre</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Prevention</keyword>
  <keyword>Probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

